They found that prior exposure to aspirin significantly associated with reduced risk of developing COVID‐19 (adjust OR 0.29, 95% CI 0.14–0.58, P < 0.001), while prior use of COX‐2 inhibitors did not significantly reduce the risk (Huh et al., 2020). Here, PTGS2 is linked to COVID-19.